Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...

Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Editas Medicine (EDIT – Research Report), ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Oppenheimer analyst Jay Olson maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Given the large stake in the stock by institutions, Editas Medicine's stock price might be vulnerable to their trading ...

On Friday, Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $3.36 which represents a slight increase of $0.05 or 1.51% from the prior close of $3.31. The stock opened at $3.32 ...

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, and Genevant Sciences, a leading nucleic acid ...

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and ...